Health Care Reform's 340B Provisions Could Impact Oncology Near-Term
Executive Summary
Companies with oncology products should take a look at the health reform law's provisions on the 340B drug discount program when assessing the new law's early impact, a review by the consulting firm KantarHealth suggests